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Abstract
Background: Cervical cancer is now considered the second leading cause of death among women
worldwide, and its incidence has reached alarming levels, especially in developing countries.
Similarly, high grade squamous intraepithelial lesion (HSIL), the precursor stage for cervical cancer,
represents a growing health problem among younger women as the HSIL management regimes that
have been developed are not fully effective. From the etiological point of view, the presence of
Human Papillomavirus (HPV) has been demonstrated to play a crucial role for developing cervical
malignancies, and viral DNA has been detected in 99.7% of cervical tumors at the later stages.
CIGB-300 is a novel cyclic synthetic peptide that induces apoptosis in malignant cells and elicits
antitumor activity in cancer animal models. CIGB-300 impairs the Casein Kinase (CK2)
phosphorylation, by targeting the substrate's phosphoaceptor domain. Based on the perspectives
of CIGB-300 to treat cancer, this "first-in-human" study investigated its safety and tolerability in
patients with cervical malignancies.
Methods: Thirty-one women with colposcopically and histologically diagnosed microinvasive or
pre-invasive cervical cancer were enrolled in a dose escalating study. CIGB-300 was administered
sequentially at 14, 70, 245 and 490 mg by intralesional injections during 5 consecutive days to
groups of 7 – 10 patients. Toxicity was monitored daily until fifteen days after the end of treatment,
when patients underwent conization. Digital colposcopy, histology, and HPV status were also
evaluated.
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Results: No maximum-tolerated dose or dose-limiting toxicity was achieved. The most frequent
local events were pain, bleeding, hematoma and erythema at the injection site. The systemic
adverse events were rash, facial edema, itching, hot flashes, and localized cramps. 75% of the
patients experienced a significant lesion reduction at colposcopy and 19% exhibited full histological
regression. HPV DNA was negative in 48% of the previously positive patients. Long term follow-
up did not reveal recurrences or adverse events.
Conclusion: CIGB 300 was safe and well tolerated. This is the first clinical trial where a drug has
been used to target the CK2 phosphoaceptor domain providing an early proof-of-principle of a
possible clinical benefit.
Background
Current trends in cancer treatment focus to "targeted ther-
apy", referring to a new generation of drugs designed to
interfere with specific molecular targets that are necessary
to maintain malignant phenotype, progression or metas-
tasis [1]. Protein kinases constitute promising classes of
cancer targets as some specific inhibitors have shown clin-
ical benefit in patients [2,3]. CK2 is involved in the tumor
cell adaptive response and protection against apoptosis
[4]. It is uniformly deregulated 3- to 7-fold in different
cancer types [5] and has been associated with aggressive
tumor behavior in human head and neck carcinoma [6].
E7 viral oncoprotein phosphorylation by CK2 plays an
important role on HPV malignant properties [7].
Although no previous clinical trials with CK2 inhibitors
have been reported so far, promising preclinical results
indicate that it could be a good molecular target for cancer
therapy [8].
CIGB-300 is a cyclic peptide that impairs CK2 phosphor-
ylation after intracellular delivery. It behaves as pro-apop-
totic both on HPV-positive and -negative tumor cell lines.
Intralesional injections of the drug induced a vigorous
antitumor effect on HPV-positive solid tumors in mice
[9]. Therefore, it was hypothesized that local CIGB-300
injections could exhibit clinical benefit in patients with
cervical malignancies.
Being the first-in-human application of CIGB 300 or any
CK2 inhibitor, the trial reported here was done to investi-
gate the safety and tolerability of this peptide-based drug
after local injections. Besides, efficacy signs were also
explored in order to provide an early proof-of-principle
for CIGB-300 as a modality of targeted cancer therapy in
cervical malignancies.
Methods
The study followed the principles of the Declaration of
Helsinki for investigations in humans. It was approved by
the Ethics and Scientific Committees of the participant
institutions and by the Cuban Regulatory Authority.
Patients with colposcopical and cytological suspect of
HSIL or microinvasive cervical cancer were recruited at
specialized services from seven gyneco-obstetric hospitals
throughout Havana and other provinces. They were then
evaluated at the National Reference Center for Cervical
Cancer at the "Clodomira Acosta" Hospital, where the eli-
gibility criteria were verified. Product administrations and
evaluations took place, as in-patients, at the National
Center for Toxicology, in a specialized facility for clinical
Pharmacology studies.
Patient Eligibility
Patients were included if they were 18 to 65 years-old, had
histological diagnosis of HSIL or epidermoid microinva-
sive cervical cancer (FIGO Classification Stage 1A1)[10],
with larger diameter ≥ 3 mm by video-colposcopy, corre-
sponding with major changes or infiltrating stage accord-
ing to the International Federation of Cervical Pathology
and Colposcopy [11], and gave their written, informed
consent to participate. Exclusion criteria were to have
received chemotherapy or surgical, ablative, radiant, or
immunomodulator treatment, up to 3 months before
inclusion, psychiatric dysfunctions, pregnancy and breast-
feeding, chronic diseases such as asthma, epilepsy,
autoimmune diseases, hypertension, anemia, acute sys-
temic or genital tract infections, renal, hepatic and cardio-
vascular disorders
Study Design and Treatment Plan
The design was an open, uncontrolled, dose-escalating
trial. The four dose levels (14, 70, 245 and 490 mg) were
tested sequentially. The protocol previewed that the next
dose level would be undertaken after the safety of the pre-
vious one was assured when no severe adverse events (AE)
occurred up to 20 days after the first administration. Sam-
ple size for each group was previewed as between 7 and 10
patients. This N range assured that if no severe adverse
reaction appeared, the probability of its occurrence would
be less than 20%, with an 80%–90% confidence interval.
Since patients of the same group were treated the same
days, the exact number of subjects in each group wasBMC Cancer 2009, 9:146 http://www.biomedcentral.com/1471-2407/9/146
Page 3 of 9
(page number not for citation purposes)
finally determined by practicalities such as the number of
patients recruited that week.
CIGB-300 was synthesized and supplied by the Center for
Genetic Engineering and Biotechnology in 245 mg vials,
as a lyophilized powder. It was reconstituted with 1 mL of
water for injection and subsequent dilutions were pre-
pared to a final volume of 1 mL for groups I and II that
received less than 245 mg per dose. Groups III and IV
received one and two vials per administration, respec-
tively.
One milliliter containing the corresponding drug dose
was evenly distributed among four previously defined
quadrants on the cervical lesion area. Injections were
approximately 2 mm deep and were given for 5 consecu-
tive days. Fifteen days after treatment cessation all patients
underwent conization by loop electrosurgical excision
procedure (LEEP). Concomitant interventions could be
taken to manage the AE, according to established clinical
practices. Since allergic-like reactions appeared with the
lower dose levels, prophylactic antihistaminic medication
(50 mg intramuscular diphenhydramine) was given 20
minutes before CIGB 300 injections to groups III and IV.
Evaluation
Pretreatment evaluation included a detailed history, phys-
ical and colposcopical examinations, and HPV testing.
Besides, electrocardiogram, hematological counts, blood
chemistry, coagulation and cervix microbiological studies
were done. Twenty-four hours after the fifth CIGB-300
administration and 15 days after treatment cessation these
evaluations were repeated. Additionally, patients were fol-
lowed clinically and colposcopically at 3, 6, 9, and 12
months after the conization. Papanicolau's test was done
at these moments as well.
Since the main purpose of the trial was to evaluate the
product's safety, local and systemic AE were carefully
screened up. A colposcopic examination of the whole cer-
vix area was carefully performed daily during the consec-
utive 5-day drug regimen, 24 hours after the last
administration and 15 days later. Likewise, systemic toxic-
ity was evaluated during 24 hours after each CIGB-300
administration, including cardiovascular monitoring dur-
ing the injections and vital signs measurements (tempera-
ture, heart and respiratory frequencies, and blood
pressure) 30 min. after the end of the injection, then every
hour during 4 hours and every 4 hours thereafter.
The medical terminology for AE and their severity classifi-
cation (in grades) used were those of the Cancer Therapy
Evaluation Program, Common Terminology criteria [12].
In general, this classification consists in 5 grades: (1) mild
if no therapy is necessary, (2) moderate if specific treat-
ment is needed, (3) severe when hospitalization or its pro-
longation was required, (4) very severe if a reaction was
potentially life-threatening, and (5) when contributed to
the patient's death.
A qualitative assessment was used to classify the causal
relationship as definite, probable, possible or doubtful
[13]. A reaction was classified as "definite" if (1) followed
a reasonable temporal sequence after drug administra-
tion; (2) followed a known pattern of response to the
drug; (3) could not be explained by concurrent disease or
other drugs; and (4) was confirmed by improvement
upon drug removal and by reappearance on re-challenge.
It was considered as "probable" if it had criteria (1), (2),
(3) and was confirmed on drug suspension but not on re-
challenge. A reaction was defined as "possible" if followed
a reasonable time sequence to the drug administration,
but could also be explained by concurrent disease or other
drugs. Finally, a reaction that was more likely related to
factors other than the suspected drug was classified as
doubtful.
Colposcopical evaluations were done using a video col-
poscopy device (Mediscope, Medison, Korea) with a cali-
brated rack to standardize imaging distance and
illumination. Lesions were examined by two different spe-
cialists after applying 5% acetic acid for 3 min. They were
described according to the Barcelona 2002 classification
[11] and their morphometric analysis was done with vali-
dated software for quantitative digital image evaluation
(MADIP® V.4; Institute of Cybernetics, Mathematics and
Physics, Havana)
Histological analyses were performed on colposcopically
directed biopsies from abnormal areas taken before treat-
ment and afterwards in the cone specimen. Permanent
sections were subsequently prepared, stained with hema-
toxylin-eosin and finally reviewed by two different
pathologists who classified the lesions according to the
FIGO Classification.
The presence of HPV DNA in biopsies was examined
before and after CIGB-300 treatment by PCR using a pair
of L1-consensus primers (GP5+/GP6+) [14]. The HPV
DNA detection limit was about 310 viral copies. Addi-
tional PCR with specific HPV-16 and -18 primers was per-
formed for typing [15] and HPV DNA levels were
normalized with those corresponding to β-globin as
housekeeping gene.
Response Criteria and Clinical Activity
The total lesion area (TLA) was the parameter evaluated
for colposcopical response. Response was defined accord-
ing to the RECIST criteria [16]. Complete response was
considered as disappearance of all high grade lesions; par-BMC Cancer 2009, 9:146 http://www.biomedcentral.com/1471-2407/9/146
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tial response if at least a 30% TLA decrease was observed;
stable disease if changes were within -30% and + 20%
regarding initial TLA; progressive disease meant at least a
20% TLA increase.
The histological response was based on the lesions phase
changes. A complete response was defined as the absence
of high grade lesions 15 days after drug administration;
partial response when a down-staging of the high grade
lesion occurred, and progression if there was up-staging.
Statistics
It was not an objective of the study to compare the effect
of the different CIGB-300 doses among them but to test
each one in terms of tolerability and a preliminary efficacy
evaluation. Therefore, dose groups were sequential and
not the product of randomization.
Continuous variables were analyzed for normal distribu-
tion using the Shapiro-Wilk's test. They are presented as
mean ± standard deviation (SD) or median ± interquartile
range (QR). Categorical variables are presented as propor-
tions. The correlation between the number of local AE and
the total dose was estimated using the Pearson's correla-
tion coefficient. The level of significance chosen was 0.05.
Results
Patient Characteristics and Dosing History
Eighty patients from the seven participating recruiting
centers were evaluated from January to July 2006. Of
them, 31 were enrolled. Their demographic and baseline
characteristics are outlined in Table 1. Age ranged from 20
to 54 years and lesion area between 18 and 319 mm2.
Most of the lesions (16; 52%) were carcinoma in situ; 14
(45%) were CIN and there was one microinvasive carci-
noma. HPV DNA was detected in 22/28 biopsies (79%; 3
samples were not useful for PCR). All were HPV 16 except
for one HPV 18 and two non 16/non 18 types.
Table 1: Individual patient data
Patient No. CIGB-300
(mg)
Age Total lesion area (mm2) Histological diagnosis HPV status
Initial End Initial End Initial End
1 14 28 289.1 187.1 CIN III CIN III 16 16
2 14 42 186.9 117 CIN III MIC 16 16
3 14 35 165.3 126.05 CIN III CIN III Neg Neg
4 14 33 128.6 69.59 CIN III CIN III 16 16
5 14 33 17.7 13.4 MIC CIN III Neg Neg
6 14 31 103.3 0 CIN III Koilocytosis 16 Neg
7 14 43 93.2 45.8 CIN III CIN III 16 16
8 14 40 62.3 17.1 CIN III CIN III 16 Neg
9 70 34 64.8 19.6 CIN III CIN III 16 Neg
10 70 52 72.8 5.1 CIN II Koilocytosis 16 16
11 70 30 55.9 21.5 CIN II CIN II Neg Neg
12 70 54 36.8 7.6 CIN II CIN II Neg Neg
13 70 36 39.6 0 CIN II CIN I 16 Neg
14 70 20 36.1 0 CIN III Koilocytosis Neg 16
15 70 27 73.3 38.4 CIN III CIN III 16 Neg
16 70 27 93.6 34.1 CIN III CIN III N16-N18 Neg
17 245 31 219 134 CIN III CIN III 16 16
18 245 40 80.7 5 CIN III CIN III 16 16
19 245 33 87.8 77 CIN III CIN III 16 Neg
20 245 26 176 8.11 CIN III CIN III N.D. N.D.
21 245 40 85 0 CIN III CIN III 18 18
22 245 21 30.2 0 CIN III Neg N.D. N.D.
23 245 26 64.8 0 CIN III Koilocytosis N.D. N.D.
24 490 41 247 38 CIN II CIN III Neg Neg
25 490 29 319 77 CIN II CIN III 16 Neg
26 490 31 213 38 CIN II MIC 16 Neg
27 490 33 23 5 CIN III CIN II 16 16
28 490 39 215 73 CIN III CIN III 16 N.D.
29 490 46 30.3 2.1 CIN III CIN III N16-N18 Neg
30 490 40 249 55 CIN III CIN III 16 16
31 490 42 144 38 CIN III CIN III 16 16
Abbreviations: CIN II-III (cervical intraepithelial neoplasia, grade II or III), MIC (microinvasive carcinoma), Neg: Negative, N16-N18: Non-16 Non 
18, ND (not determined)BMC Cancer 2009, 9:146 http://www.biomedcentral.com/1471-2407/9/146
Page 5 of 9
(page number not for citation purposes)
The treatment schedule was completed in 30 patients
(97%). One did not conclude the assigned scheme (490
mg per dose, group IV), due to a transient vasovagal syn-
drome with loss of consciousness that was classified as a
severe event (grade 3). She received only 77 mg of the
drug at the first application and the interruption was per-
manent.
Local and Systemic Toxicity
All patients experimented some local or systemic AE. A
total of 409 events were recorded, 337 (82%) mild, 71
(17%) moderate and only one AE was classified as severe.
The most frequent local AE were bleeding, pain on lower
abdomen, hematoma, ulcer, necrosis, erythema, and
edema on the injection site (Table 2). There was a signifi-
cant correlation with respect to the total dose received and
the number of local AE (r2 = 0.469, p = 0.008). All local AE
were grade 1 except for 2 ulcers in group II, 2 ulcers, 2
hematoma and 2 necrosis in group III, and 2 hematoma
and necrosis in group IV, which reached grade 2. Twenty-
two patients had either local or systemic grade 2 AE. The
colposcopic examination 15 days after CIGB-300 treat-
ment evidenced a complete recovery of all the local AE.
Table 3 lists the clinically relevant systemic toxicities
observed during the study. The most frequent were aller-
gic-like reactions including rash, facial edema, itching, hot
flashes, extensive bumps, localized cramps and tachycar-
dia. The rate of these AE decreased with the subsequent
CIBG 300 administrations (data not shown). Prophylactic
antihistaminic medication greatly ameliorated some of
the systemic allergic-like AE in cohorts III and IV (local-
ized rash and localized bumps) (Table 3). Four vasovagal
syndromes were observed; one of them was grade 3 since
the patient lost her consciousness transiently (1 min). Its
association to CIGB-300 was not demonstrated.
There were no differences between baseline and post-
treatment blood counts, serum chemistry results, coagula-
tion parameters and electrocardiograms (data not
shown).
Efficacy analysis
Individual efficacy results are shown in Table 1 and sum-
marized in Table 4. TLA decreased in all patients at colpos-
copy 15 days after CIGB-300 treatment. Colposcopic
response was evidenced in 28/31 patients (90%), six of
them (19.4%) complete. Response rates were above 75%
in all groups. Histological analyses indicated that 19.3%
of the patients (6/31) experienced full regression after
treatment while 25.8% (8/31) had histological grade
down-staging. Responses were 10/16 (62.5%) for cases
with carcinoma and 5/9 (55.6%) for patients with CIN.
HPV status became undetectable in 48% (10/21) of the
initially HPV-positive patients from all dose cohorts. One
patient was not evaluated after treatment.
Long term follow-up
None of the patients showed confirmed lesion recurrence
during the 12-months follow-up. There were no late
adverse events either. Interestingly, 4 patients became
pregnant, two of them with previous infertility history,
with successful, normal neonates.
Discussion
CIGB-300, a novel inhibitor of the CK2 phosphorylation,
was safe and well tolerated in this study. No severe drug-
related adverse reactions were observed. Intralesional
application of CIGB-300 at a daily dose range from 14 to
Table 2: Frequency and distribution of the local adverse events (percents refer to the total number of events within each group)
Local Events Group I
(14 mg)
Group II
(70 mg)
Group III
(245 mg)
Group IV
(490 mg)
Bleeding 9 (47.4%) 22 (57.9%) 5 (14.7%) 16 (39.0%)
Pain in lower abdomen 0 6 (15.8%) 10 (29.4%) 8 (19.5%)
Hematoma 0 3 (7.9%) 7 (20.6%); g2: 1 (2.9%) 4 (9.8%); g2: 1 (2.4%)
Ulcer or superficial necrosis 0 6 (15.8%); g2: 6 (15.8%) 3 (8.8%); g2: 3 (8.8%) 6 (14.6%); g2: 4 (9.8%)
Erythema in situ* 2 (10.5%) 0 3 (8.8%) 6 (14.6%)
Edema in situ* 4 (21.0%) 0 3 (8.8%) 1 (2.4%)
Vaginal burning 2 (10.5%) 0 2 (5.9%) 0
Spontaneous peeling 1 (5.3%) 1 (2.6%); g2: 1 (2.6%) 0 0
Pain in situ* 1 (5.3%) 0 0 0
Color change at puncture site 0 0 1 (2.9%) 0
Total 19 38 34 41
*: In situ events referrer to the localization of such events at the site of injection. All events are grade 1 (mild) if not specified; g2: grade 2 
(moderate).BMC Cancer 2009, 9:146 http://www.biomedcentral.com/1471-2407/9/146
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490 mg through a consecutive-5 day regimen seems to be
a safe approach. The dose range and therapeutic regimen
were selected according to an extrapolation made from
previous toxicological (data not published) and pharma-
codynamic studies in animal models. It was not an objec-
tive of the study to compare the effect of the different
CIGB-300 doses among them but to test each one in terms
of tolerability and a preliminary efficacy evaluation.
Although neither the MTD nor DLT were found, the most
frequent systemic and local toxicities produced by the int-
ralesional administration of CIGB-300 were identified,
The appearance of some transient systemic "allergic-like"
events could be explained by a potential histamine release
from local mastocytes. Accordingly, prophylactic antihis-
taminic medication of patients exposed to the higher dose
levels ameliorated the systemic localized rash and bumps.
As CIGB-300 inhibits CK2 phosphorylation, inducing
apoptosis on the target cells, mastocyte death and the sub-
sequent histamine release to the circulation should not be
discarded and merits further investigation. However,
other drugs such as interferons [17-19], which induce
apoptosis by other mechanisms that exclude CK2, have
been also locally administrated on the cervix without sys-
Table 3: Frequency and distribution of the systemic events occurred at each dose level
Systemic Events Group I
(14 mg)
Group II
(70 mg)
Group III
(245 mg)
Group IV
(490 mg)
Itching 8 (14.6%) 18 (25.0%) 29 (25.9%) 29 (32.3%) 84
Hot flashes 12 (21.8%) 14 (11.7%) 8 (7.1%) 8 (8.9%) 42
Localized rash 3 (5.4%) 21 (17.5%) 6 (5.4%) 8 (8.9%) 38
Localized facial edema 9 (16.4%) 6 (5.0%) 8 (7.1%) 13 (14.4%) 36
Bumps 0 12 (10.0%) 17 (15.2%) 6 (6.7%) 35
Extensive rash 2 (3.6%) 0 21 (18.8%) 5 (5.6%) 28
Cramps 3 (5.4%) 2 (1.7%) 11 (9.0%) 6 (6.7%) 22
Headache 3 (5.4%) 2 (1.7%) 4 (3.6%) 2 (2.2%) 11
Metallic flavor 4 (7.3%) 6 (5.0%) 1 (0.9%) 0 11
Tickling or tingling 5 (9.1%) 6 (5.0%) 0 0 11
Tachycardia 0 7 (5.8%) 3 (2.7%) 0 10
Tinnitus 0 7 (5.8%) 0 0 7
Nausea 0 3 (2.5%) 1 (0.9%) 3 (3.3%) 7
Facial erythema 0 7 (5.8%) 0 0 7
Palpitations 0 2 (1.7%) 1 (0.9%) 2 (2.2%) 5
Hypertension 3 (5.4%) 1 (0.8%) 0 1 (1.1%) 5
Vasovagal syndrome 0 g2: 2 (1.7%) g3: 2 (2.2%) 4
Dizziness 1 (1.8%) 2 (1.7%) 0 0 3
Tremors 0 0 0 3 (3.3%) 3
Vomiting 0 2 (1.7%) 0 0 2
Fast breathing 1 (1.8%) 0 0 0 1
Abdominal pain 1 (1.8%) 0 0 0 1
Arrhythmia 0 0 0 1 (1.1%) 1
Hypotension 0 0 1 (0.9%) 0 1
Posture-related tremor in lower limbs 0 0 0 1 (1.1%) 1
Red eyes 0 0 1 (0.9%) 0 1
Total 55 120 112 90
Table 4: Efficacy evaluation of CIGB-300 administration.
Group I
(14 mg)
Group II
(70 mg)
Group III
(245 mg)
Group IV
(490 mg)
TLA
(mean ± SD)
Initial (mm2) 15.7 ± 10.4 7.6 ± 2.7 10.0 ± 7.8 14.5 ± 15.5
Final (mm2) 9.9 ± 19.6 2.8 ± 3.9 1.4 ± 14.0 5.0 ± 5.9
% Reduction 41.6 ± 41.3 74.6 ± 36.2 95.4 ± 61.2 81.3 ± 19.7
Responders Colposcopy 6/8 (75.0%) 8/8 (100%) 6/7 (85.7%) 8/8 (100%)
Histology 1/8 (12.5%) 3/8 (37.5%) 2/7 (28.6%) 0/8 (0.0%)
HPV status 2/6 (33.3%) 4/5 (80.0%) 1/4 (25.0%) 3/6 (50.0%)BMC Cancer 2009, 9:146 http://www.biomedcentral.com/1471-2407/9/146
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temic "allergic-like" reactions. Alternatively, this syn-
drome could be related to CIGB 300's molecular structure,
composed by several predominantly positively charged
aminoacids that make it a very basic peptide and, there-
fore, behave as a potential histamine releaser [20].
The vasovagal events (n = 4), including the only grade 3
AE observed in the highest dose group, do not seem to be
drug-related but rather associated to the mode of applica-
tion. Vasovagal events have been reported during uterine
cervix manipulation with different techniques [21].
The local toxicity, as evidenced by the total number of
these adverse events, was dose-dependent. Importantly,
cervix examination 15 days after treatment showed that all
these local AE had completely disappeared. Thus, the
short-lasting of the local AE observed make this approach
safe to treat cervical malignancies.
The standard treatments for HSIL patients, such as LEEP,
laser, cold knife conization and cryotherapy yield satisfac-
tory results. However, these procedures are not exempt of
complications and undesired effects such as cervical
obstruction, which is mostly linked to fertility limitations
[22]. Events of this magnitude were not observed during
the intralesional CIGB-300 administration and the genital
area integrity was preserved. In fact, four pregnancies were
achieved, two of them in previous apparently infertile
women.
Products such as imiquimod, administered in a gel formu-
lation has been extensively used to treat intraepithelial
lesions and genital warts [23], but local adverse reactions
leading to treatment interruption in some patients have
been also reported [24]. In the present study, neither the
local nor systemic CIGB 300-related toxicity lead to treat-
ment interruption, at least with this therapeutic regimen.
Importantly, long-term follow-up indicated that neither
local nor systemic CIGB-300-related toxicity appeared in
patients after 3, 6 and 12 months of completion the drug
administration.
The promising antitumor effect of CIGB-300 found in pre-
clinical studies, lead to the hypothesis that this pro-apop-
totic peptide could exhibit anti-neoplastic effect on
cervical malignancies when administered directly on the
transformed cervix epithelium. The results obtained seem
consistent with the initial hypothesis. For instance, the
colposcopic end-point demonstrated a significant
response rate in the entire CIGB-300 dose range as evi-
denced by the TLA reduction and the responder rates in all
the cohorts after a short period of time (15 days). Further
studies should determine whether longer treatment or fol-
low-up periods are required for maximal efficacy. Simi-
larly and equally important is that CIGB-300 treatment
lead to a full histological regression in 19% of the
patients. This means that CIGB-300 can be able to exhibit
a beneficial effect in terms of the cure or reduction of the
initial lesion. According to the natural history of the dis-
ease, spontaneous regression of NIC II and III after several
months is found in 43% and 32% of the patients, respec-
tively [25]. Contrarily, the histological and colposcopic
regression rates observed in this study seem to be drug-
related as they occurred in a very short period (15 days).
Additionally, no recurrences appeared during one-year
follow up. However, efficacy was not the main objective
of this study. Therefore such results can just be taken as
preliminary. It is additionally difficult to evaluate each
case according to histology since the initial biopsy was
taken from the apparently more representative zone of the
lesion but the final biopsy comprises the whole lesion, so
this last evaluation was more exhaustive. Future placebo-
controlled studies are needed to asses this criterion since
these lesions are usually heterogeneous and not treat-
ment-related changes in histological degree in the same
patient can occur.
HPV status has been considered as a robust and predictive
biomarker of NIC recurrence and evolution to cancer in
many clinical trials [26,27]. The result of this biomarker
evaluation in this study showed that CIGB-300 exhibited
an objective effect on virus presence. Forty-eight percent
of initially HPV-positive patients experienced a complete
virological response in the residual lesion after CIGB-300
administration. Although not all the cervix area was
checked for HPV infection after drug administration, the
fact that undetectable HPV levels were verified at the col-
poscopically directed biopsy is of great interest. The anti-
HPV response observed in some patients could be reason-
ably explained by a potential apoptotic effect that elimi-
nated the HPV-transformed cells during the consecutive 5-
day CIGB-300 regimen.
Other molecular biomarkers (apoptosis mediators, CK2
phosphorylation status) were not studied because the sec-
ond biopsy was taken 15 days after the last administration
to coincide with the therapeutic cone. At that moment it
is unlikely that these pharmacodynamic markers would
have given any significant result since their changes are
transiently regulated. An additional biopsy, close to end
of treatment (day 5 or 6) would had been necessary for
that purpose. However, this intervention was not ethically
feasible and at the same time could have influence on the
clinical outcome two weeks later.
This report describes the first clinical trial where a drug has
been used to target the CK2 phosphorylation domain. The
data reinforce the concept that CK2 phosphorylation rep-
resents a target with perspectives for cancer therapy, pro-
vide an early proof-of-principle of clinical benefit of a CK2BMC Cancer 2009, 9:146 http://www.biomedcentral.com/1471-2407/9/146
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inhibitor to treat cervical malignancies, and suggest that
CIGB-300 could represent a candidate drug for targeted
cancer therapy.
Conclusion
The CIGB-300 is a peptide-based drug that was safe and
well tolerated when administered by intralesional injec-
tions. Neither a specific maximum-tolerated dose nor
dose-limiting toxicity was identified, but given the efficacy
signs observed at all dose levels tested, the total dose range
from 14 to 490 mg is recommended for phase 2 trials.
CIGB-300 treatment indicated clinical activity, as evi-
denced by the colposcopy, histology and the effective
anti-HPV response. Such clinical effects should be con-
firmed in further controlled trials.
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